Терапевтический архив (Dec 2021)
Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial
- Gregory P. Arutyunov,
- Yuri M. Lopatin,
- Aleksandr S. Ametov,
- Fail T. Ageev,
- Mikhail B. Antsiferov,
- Svetlana V. Villevalde,
- Nadezhda G. Vinogradova,
- Gagik R. Galstyan,
- Albert S. Galyavich,
- Sergey R. Gilyarevskiy,
- Maria G. Glezer,
- Igor V. Zhirov,
- Mikhail V. Ilyin,
- Anastasiya Iu. Lebedeva,
- Sergey M. Nedogoda,
- Vladimir V. Salukhov,
- Ekaterina I. Tarlovskaya,
- Sergey N. Tereshchenko,
- Igor V. Fomin,
- Iurii Sh. Khalimov,
- Niaz R. Khasanov,
- Dmitriy V. Cherkashin,
- Sergey S. Yakushin
Affiliations
- Gregory P. Arutyunov
- ORCiD
- Pirogov Russian National Research Medical University
- Yuri M. Lopatin
- ORCiD
- Volgograd State Medical University
- Aleksandr S. Ametov
- ORCiD
- Russian Medical Academy of Continuous Professional Education
- Fail T. Ageev
- ORCiD
- National Medical Research Center of Cardiology
- Mikhail B. Antsiferov
- ORCiD
- Endocrinology Dispensary
- Svetlana V. Villevalde
- ORCiD
- Pirogov Russian National Research Medical University
- Nadezhda G. Vinogradova
- ORCiD
- Privolzhsky Research Medical University
- Gagik R. Galstyan
- ORCiD
- Endocrinology Research Centre
- Albert S. Galyavich
- ORCiD
- Kazan State Medical University
- Sergey R. Gilyarevskiy
- ORCiD
- Russian Medical Academy of Continuous Professional Education
- Maria G. Glezer
- ORCiD
- Sechenov First Moscow State Medical University (Sechenov University)
- Igor V. Zhirov
- ORCiD
- Russian Medical Academy of Continuous Professional Education
- Mikhail V. Ilyin
- ORCiD
- Yaroslavl State Medical University
- Anastasiya Iu. Lebedeva
- ORCiD
- Pirogov Russian National Research Medical University
- Sergey M. Nedogoda
- ORCiD
- Volgograd State Medical University
- Vladimir V. Salukhov
- ORCiD
- Kirov Military Medical Academy
- Ekaterina I. Tarlovskaya
- ORCiD
- Privolzhsky Research Medical University
- Sergey N. Tereshchenko
- ORCiD
- National Medical Research Center of Cardiology
- Igor V. Fomin
- ORCiD
- Privolzhsky Research Medical University
- Iurii Sh. Khalimov
- ORCiD
- Kirov Military Medical Academy
- Niaz R. Khasanov
- ORCiD
- Kazan State Medical University
- Dmitriy V. Cherkashin
- ORCiD
- Kirov Military Medical Academy
- Sergey S. Yakushin
- ORCiD
- Pavlov Ryazan State Medical University
- DOI
- https://doi.org/10.26442/00403660.2021.12.201281
- Journal volume & issue
-
Vol. 93,
no. 12
pp. 1491 – 1497
Abstract
At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.
Keywords
- empagliflozin
- chronic heart failure
- hospitalization
- decompensation of chronic heart failure
- cardiovascular mortality
- chronic kidney disease
- emperor-preserved trial
- emperor-reduced trial
- empa-reg outcome trial
- clinical inertia
